Phase 1 of EC1169 In Patients With Recurrent MCRPC

This is a Phase 1, multicenter, open-label, non-randomized, oncology study to conducted in 2 parts. Part A is a dose-escalation phase to determine the Recommended Phase 2 (RP2) dose and the following : * Evaluate the administration of EC1169 QW on Weeks 1 and 2 of a 3-week schedule * Evaluate the safety and pharmacokinetic profile of EC1169 and EC0652 * To assess preliminary efficacy results in patients with metastatic, castration-resistant prostate cancer (mCRPC) who have progressed on abiraterone and/or enzalutamide, and previously treated with a taxane. The primary objective of Part B is to identify the radiographic progression-free survival (rPFS) in taxane-naïve and taxane-exposed PSMA-positive mCRPC patients receiving treatment with EC1169.